Avidity Biosciences Reports the Data from P-I/II (EXPLORE44) Study of Delpacibart Zotadirsen (Del-zota) to Treat Duchenne Muscular Dystrophy
Shots:
- The P-I/II (EXPLORE44) study is assessing SAD & MAD of del-zota (IV) in healthy subjects & patients with DMD mutations amenable to exon 44 skipping; recruitment is completed. Individuals with DMD44 can also join EXPLORE44-OLE extension study
- Initial evaluation was carried out among 25 subjects in 2 dose levels (5 & 10mg/kg). In the 5mg/kg cohort, 10 individuals received 3 doses of del-zota or PBO (Q6W) over 4mos. to assess muscle delivery, exon skipping, dystrophin production & creatine kinase
- Results showed unsurpassed 200 nM PMO delivery in skeletal muscle, 37% increase in exon 44 skipping (up to 66%), a 25% increase in dystrophin production (54% of normal was restored) & >80% reduction in creatine kinase levels to near normal
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
